key: cord-1021703-zzhb6ko7
authors: Zhao, Yongliang; Ni, Wenjia; Liang, Simeng; Dong, Lianghui; Xiang, Min; Cai, Zeng; Niu, Danping; Zhang, Qiuhan; Wang, Dehe; Zheng, Yucheng; Zhang, Zhen; Zhou, Dan; Guo, Wenhua; Pan, Yongbing; Wu, Xiaoli; Yang, Yimin; Jing, Zhaofei; Jiang, Yongzhong; Chen, Yu; Yan, Huan; Zhou, Yu; Xu, Ke; Lan, Ke
title: Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein
date: 2021-12-23
journal: bioRxiv
DOI: 10.1101/2021.12.21.473594
sha: 9318253b3d470736920ed01dde8f97d623937834
doc_id: 1021703
cord_uid: zzhb6ko7

SARS-CoV-2 continued to spread globally along with different variants. Here, we systemically analyzed viral infectivity and immune-resistance of SARS-CoV-2 variants to explore the underlying rationale of viral mutagenesis. We found that the Beta variant harbors both high infectivity and strong immune resistance, while the Delta variant is the most infectious with only a mild immune-escape ability. Remarkably, the Omicron variant is even more immune-resistant than the Beta variant, but its infectivity increases only in Vero E6 cells implying a probable preference for the endocytic pathway. A comprehensive analysis revealed that SARS-CoV-2 spike protein evolved into distinct evolutionary paths of either high infectivity plus low immune resistance or low infectivity plus high immune resistance, resulting in a narrow spectrum of the current single-strain vaccine. In light of these findings and the phylogenetic analysis of 2674 SARS-CoV-2 S-protein sequences, we generated a consensus antigen (S6) taking the most frequent mutations as a pan-vaccine against heterogeneous variants. As compared to the ancestry SWT vaccine with significantly declined neutralizations to emerging variants, the S6 vaccine elicits broadly neutralizing antibodies and full protections to a wide range of variants. Our work highlights the importance and feasibility of a universal vaccine strategy to fight against antigen drift of SARS-CoV-2.

Since the outbreak of the SARS-CoV-2 in late 2019, it has caused a global pandemic that is still going on (1-3). Globally, on December 14, 2021, there have been 270,031,622 confirmed cases of including 5, 310, 502 deaths, reported to WHO (https://covid19.who.int/). As an RNA virus of long genome size, the SARS-CoV-2 has a relatively high mutation frequency so that various mutations have appeared after nearly two years of continuous transmission (https://bigd.big.ac.cn/ncov/variation/annotation), especially mutations on S protein would change the infectivity and antigenicity of the virus (4). The firstly identified prevalent mutation was D614G located in the SD2 domain, which altered the fusion-competent confirmation of S protein and enhanced the ACE2-binding ability (5). Subsequently, the A222V mutation detected in Spain spread quickly throughout Europe in the middle of 2020 (6). As the different mutants occur constantly, the term "variant" has been used to denote viral strains that carry a series of co-emerging amino-acid mutations (7). The WHO has recently announced a Greek alphabet-based naming scheme for variants, including variants of concern (VOC) and variants of interest (VOI) (https://www.who.int/activities/tracking-SARS-CoV-2-variants/tracking-SARS-CoV-2-variants). concerns about the effectiveness of the vaccines approved so far. Therefore, redesign and update of SARS-CoV-2 vaccines to be universally protective to heterogeneous variants is in urgent need.

In the present study, we defined the infectivity and immune-escape ability of 54 (covering 45 single mutations, 8 variants, and WT) SARS-CoV-2 pseudoviruses, and then analyzed the evolutional route of SARS-CoV-2 spike protein. We found that SARS-CoV-2 spike protein evolves into distinct evolutionary paths of either high infectivity plus low immune resistance or low infectivity plus high immune resistance, resulting in heterogenous antigenicity. Thus, the current single-strain vaccine could provide narrow-spectrum protection only to one group of variants but not to the others. By phylogenetic analysis of 2674 S proteins, we generated a consensus S 6 vaccine taking the most frequent mutations that could elicit broadly strong neutralization to all the VOC and VOI variants up to date. This study light with new hope that a universal SARS-CoV-2 vaccine is feasible and superior when facing continuous viral mutagenesis.

The frequencies of SARS-CoV-2 variants from the beginning of the COVID-19 pandemic until Dec 2021 were shown in Figure 1a . To explore the functions of SARS-CoV-2 variants and mutants, we generated 54 pseudotyped viruses expressing either ancestry S WT or mutated S proteins (covering 45 single-site mutations and 8 defined variants generated in a 614G background) (illustrated in Fig. S1 ). The infectivity assays were performed with four SARS-CoV-2-susceptible cell lines: BHK21-hACE2, Vero E6, 27) . As summarized in Figure 1b (also shown in Fig. S2 (Fig. 1b) . On the contrary, some mutations counteracted each other, such as E484K and T1027I mutations neutralized the enhanced infectivity of H655Y to weaken viral infectivity of the Gamma variant (P.1) (Fig. 1b) . Similarly, the E484K and del69-70 mutations also reduced Q52R infectivity in the Eta variant (Fig. 1b) . In summary, single mutations in the NTD region from VOC or VOI could either increase or decrease the infectivity but mutations in the RBD region mainly enhance viral infectivity except for E484K (Fig. 1c) . Interestingly, mutations in the S2 subunit, such as S982A and D950N in the HR1 region strongly enhanced viral infectivity indicating the S2 subunit also plays an essential role in regulating viral infectivity.

To study the immune-escape abilities of S mutants, we test all the 54 pseudoviruses against a set of 14 monoclonal neutralizing antibodies targeting either WT S1 or RBD (Table S1 , as a control, 14 of 27 commercial monoclonal antibodies could effectively neutralize the D614G variant in Fig.   S3 ). Viral sensitivities to neutralization were calculated by neutralizing percentages relative to that of the reference D614G variant under the NT 50 -dilution to D614G variant for each antibody.

Based on the relative neutralization activities, the 14 tested antibodies can be divided into four classes ( Fig. 2a left and even gained resistance to the class IV antibody (Fig.2a , the far-right panel).

To understand the evolutional tendency of the SARS-CoV-2 spike protein, we generated a quadrantile diagram combined with isolates numbers to present the infectivity (Y-axis) and

immune-escape (X-axis) of SARS-CoV-2 S protein based on the results in Figure 1b and Figure 2a .

The color in each pie chart indicated the different isolation times of the individual variant (mutation), and the area size of each pie chart indicated numbers of isolates from January 2020 to December 5 th 2021 recorded in GISAID (the bigger size the larger number of isolates) (Fig. 2b) .

The comprehensive results from 4,710,001 S sequences showed that one set of mutations tends to increase the viral infectivity, such as del157, del157-158, S982A, H655Y, R246I, Q52R, and L452R, and another set of mutations tends to escape the antibodies such as E484K, N501Y, and E484Q. Interestingly, few mutations had a dual effect of affecting both infectivity and immune-escape ability of SARS-CoV-2.

Only the Beta variant distributed on the diagonal represented both high infectivity and high immune resistance. Of note, case numbers of the Beta variants were also small ( Fig. 2b) . Other variants with large numbers of isolates either evolved to have increasing infectivity (vertical) or high immune-escape ability (horizontal). For instance, the Delta and Lambda variants appear in the Y-axis direction with infectivity factors of 4.25 and 4.10, but they all showed low ability to escape neutralizing antibodies. On the contrary, the Eta and Gamma variants showed strong escape ability plus low infectivity appearing in the X-axis direction. The highly concerned Omicron variant is located close to the Beta variants with the highest immune-escape factor of 3.32, and high infectivity only in Vero E6 cells but low infectivity in the other three cell types. The data suggest that, in most cases, viral infectivity and immune escape ability of spike protein is contradictory. The highly infectious spike goes along with weak immune-escape ability, in contrast, the highly resistant variants work along with low infectivity. Although the prevalent situation for Omicron is still pending, the current evolutionary trend is similar to the Beta variant but it differed in cell-specific infectivity.

Obviously from Figure 2b , the S protein evolved into two distinct evolutional paths. Thus, the current single-strain vaccine strategy could protect variants from the same evolutionary path but not from another path. For instance, the S WT vaccine cannot protect the Beta or Gamma variants as efficiently as S WT or the Alpha variant. To construct a pan-vaccine to elicit broad neutralizing antibodies to variants in both paths, we generated a consensus S protein by downloading 2674

Spike protein amino-acid sequences from the NCBI database (until February 28, 2021, before Delta emerged) to build a phylogenetic tree using MEGA 10.0 software (Fig. 3a) (Figure 3b and Table   S2 ). Five mutations, D614G, del69-70, del144, N501Y, and P681H accounted for the top-five proportions (Fig. 3b ). In addition, considering the results of the neutralization experiment in Figure 2a (E484K significantly resisted to neutralizing antibodies), we design a consensus sequence of S 6 (E484K with above top-five-frequency mutations) (Fig. 3c ) and another S 15 (introducing 9 more top mutations based on S 6 ) ( Fig. S4a, b) . We further reconstructed phylogenetic trees using the eight VOC variants (two isolate sequences each) and the S 6 sequence in either a rectangle shape (Fig. 3d ) or a clock shape (Fig. 3e) . The results clearly showed that the S 6 sequence is located in the middle of the phylogenetic tree indicating its consensus characteristic.

Strikingly, although omicron emerged after we constructed the S 6 , it clustered together with the S 6 sequence in the same clade despite a far evolutionary distance from all the other variants, proofing again that the S 6 sequence is the root sequence taking the most consensus mutations ( Fig. 3d and   3e ).

During the time of preparing the manuscript. we had re-calculated the proportion of mutations base on the database update to Oct 2021 (when the Delta variant had already emerged) and ended up with the same top-five mutations in S 6 (Data not shown).

To test whether S 6 could serve as a pan-vaccine antigen against heterogeneous variants, we generated subunit vaccines by expressing S trimer of either S WT or S 6 in the CHO-K1 eukaryotic expression system. Subsequently, both S 6 and S wt antigens were mixed with adjuvants to formulate subunit vaccines, which were then used to immunize BALB/c or K18-hACE2 mice. Each mouse was immunized with 5 μ g/dose antigen with primary and boost immunization strategy in an interval of 14 days (immunization procedure shown in Fig. 4a ). The mouse sera were collected 14 days after the second vaccination.

To evaluate the immunogenicity of the S wt and S 6 vaccines, we first investigated the serum neutralizing activities from each vaccinated mouse to different pseudotyped variants under their NT 50 -dilutions to the reference D614G pseudovirus respectively. The results in Figure 4b showed that sera from the ancestry S WT vaccinated mice sharply decreased their neutralizing activities to all the VOC or VOI variants, especially to the Beta variant (2.27-fold average reduction to the reference D614G variant) and Delta variant (1.94-fold average reduction to the reference D614G variant). However, sera from S 6 -vaccinated mice exhibited a broader spectrum of neutralizing activities to all the seven variants and showed even stronger neutralization to five out of seven variants (1.06-to 1.53-fold increased to the reference D614G variant) (Fig. 4b) . A detailed serum neutralization against all the individual mutations in VOC and VOI showed that S 6 sera could neutralize better against immune-escaping mutations such as E484K, N501Y, E484Q, del69-70, F490S, P681H, and T478K (Fig. 4c) . We further evaluated NT 50 of S 6 vaccinated sera by calculating Geometric Mean Titers (GMT). The results in Figure 4d showed that S 6 -elicited NAbs neutralized WT pseudoviruses at an average GMT of 650. Meanwhile, it can also neutralize VOC and VOI pseudoviruses at the GMT range of 563-1952, indicating that the consensus S 6 vaccine had universal protections to the antigen shift of SARS-CoV-2 variants.

To our surprise, the mice serum from the S 15 vaccination did not show better neutralizing against different variants than the S 6 ( Fig. S4) , which implies that the design of vaccine antigens is not a simple superposition of mutation sites but requires joint analysis of rigorous bioinformatics calculations and experimental evidence.

Taken together, the current ancestry S WT vaccine with low neutralization to viral mutants needs to be updated to broad-reactive universal vaccines when facing the continuous antigen shit of SARS-CoV-2 variants. The results in Figure 5b showed that the neutralization titers of mice sera against the pseudotyped WT, Beta, and Delta viruses were almost equally high at GMT of 1234, 1958, and 911, respectively (Fig.5b) . The body weights of mice from the unvaccinated control group all dropped to more than 25% and died on day 6 to day 9. In contrast, the S 6 subunit-vaccine could provide 100% protection against all the three viruses (WT, Beta, and Delta) (Fig.5c ). Consistent with the body weight and survival data, S 6 subunit-vaccine reduced viral RNA load at 19677, 13650, and 36-fold in the lung of the WT, Beta, and Delta SARS-CoV-2 infected mice compared to the control group respectively (Fig.5d ).

Overall, our results confirmed that S 6 subunit-vaccine conferred broad protection against SARS-CoV-2 variants evolved from two distinct paths. It can also elicit equal effective NAbs against the emerging Omicron variant at the GMT of 1214 (Fig. 6) , suggesting that the consensus S 6 immunogen can most likely serve as a pan-vaccine to protect against potential antigen drift of SARS-CoV-2 in the future.

The emergence of a variety of SARS-CoV-2 variants has become a major concern during the pandemic. More than 6,200 types of amino acid substitutions, deletions, and insertions have been found in the SARS-CoV-2 S protein. Mutations are categorized into two directions. One makes the virus more infectious with high cell binding and entry ability which leads to more transmissible in the human population. The other enables the virus to evade the host's immune responses such as neutralizing antibodies leading to breakthrough infections after vaccination (26, 30, 31) .

In particular, L452R has been reported to increase the infectivity of the B.1.617 variant (32). For immune-escape ability, E484 is the most important amino acid. Changes of E484 to K, Q, or P reduced the neutralizing activity of antibodies to more than 10 folds (33). How SARS-CoV-2 evolves in the future is still mysteries and is far from certain.

In this study, the infectivities of 54 pseudotyped SARS-CoV-2 viruses taking individual mutations were systemically studied. We found that the significantly effective mutations mainly enriched in NTD and RBD, while mutations outside of these two domains had minimal effects on viral infectivity (Fig 1c) . To our surprise, S982A mutation, which is located in the heptad repeat 1 (HR1) domain of the S2 subunit, showed a high ability to increase viral infectivity. The HR1

domain was highly conserved among HCoVs and play an essential role during the viral membrane fusion process, serving as a broad-spectrum drug target ( As the SARS-CoV-2 spike protein evolved in two distinct directions (high infectivity with weak immune-escape or high immune-escape with low infectivity) (Fig 2b) , a universal vaccine to provide broad protection must take all the heterogeneous mutations into account within the same antigen. Here, we generated a consensus antigen (S 6 ) by phylogenetically calculating the consensus sequence which is a collective sequence including the most frequent mutations. The S 6 antigen included the top five high-frequency mutations and the most resistant mutation (E484K).

The high-frequency mutations in the S 6 antigen protected against variants with high infectivities like the Delta and Lambda variants, while the protection of high immune-escape variants was correlated with the E484K mutation. Our results showed that the S 6 antigen could elicit broad humoral immune against circulating variants including the WT, the Beta (B.1.351), and the Delta (B.1.617.2) variants. Interestingly, our S 6 antigen not only improved the protective effects of covered mutations but also elicited better neutralization activity against uncovered mutations like (E484Q, T478K, and F490S) (Fig 4c) . Consistent with this, class III and IV antibodies also showed broad-spectrum neutralization activity, suggesting that conserved epitopes might exist in SARS-CoV-2 spike protein. We further test the protection of the S 6 vaccine against the Omicron variant. Our results showed that three out of four sera of the S 6 -vaccinated mice displayed similar neutralization against the Omicron variant as compared to the WT strain, and only one S 6 -serum decreased its activity. Recent studies have shown that the neutralizing activity of sera from ancestral strain vaccine generally decreased around 22 to 41-fold against the Omicron variant (38, 39), but the majority of our S 6 sera performed better neutralization once again proofing the consensus characteristics of the S 6 vaccine.

There was a rapid development of various types of vaccine such as mRNA vaccine (40), viral vector-based vaccine (41), inactivated vaccine (42), virus-like particle vaccine (43), and subunit vaccine (44). However, the current single-strain vaccine strategy with all these vaccine types could not provide cross-variant neutralizations especially to variants from two evolutionary paths.

According to the current reports, all the ancestral S WT vaccines decrease their neutralizations to the highly evading Beta and Gamma variants (45, 46) . Convincingly, our consensus pan-vaccine strategy paves a way to fight against antigen drift of SARS-CoV-2 with great potentials.

The A549-hACE2, Caco-2, Vero E6 cell lines were obtained from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS). BHK21-hACE2 cell line was provided by Professor Huan Yan, Wuhan University.

All cells were incubated at 37 °C in 5% CO 2 .

The WT, Beta, and Delta SARS-CoV-2 viruses were kindly supplied by Hubei CDC and 

Pseudotyped VSV-ΔG viruses expressing either a luciferase reporter or mCherry reporter were provided by Professor Ningshao Xia, Xiamen University. To produce pseudotyped VSV-ΔG-Luc bearing SARS-CoV-2 spike protein (pseudo-SARS-CoV-2), Vero E6 cells were seeded in 10-cm dishes and transfected simultaneously with 15 μ g SARS-CoV-2-S-Δ18 plasmid using

Lipofectamine 2000 (Thermo). Forty-eight hours post-transfection, 500 µl pseudotyped VSV-ΔG bearing VSV-G protein was used to infect Vero E6 cells. Cell supernatants were collected after another 24 h, clearing of cell debris by centrifugation at 3000 rpm for 6 minutes, aliquoted, and stored at -80 °C.

The day before pseudoviruses titration, BHK21-hACE2 cells were seeded into 96-well culture plates at an appropriate density. To titrate the pseudoviruses, an initial 10-fold dilution in infection medium (DMEM, supplemented with 2% FBS, 1% penicillin/streptomycin) with six replicates were made in 96-well plates followed by serial 3-fold dilutions for a total of nine dilutions. The 

The day before pseudoviruses infection, the targeted cells were seeded into 96-well culture plates at an appropriate density. Using the lowest TCID 50 as a reference, the pseudoviruses were diluted to the same TCID 50 with the infection medium. After normalization, 100 μ L of the pseudovirus with 2-fold dilution was added into the targeted wells in 96-well cell culture plates. After 24 h incubation at 37 °C with 5% CO 2 , the cells were washed with cold PBS and lysed in 40 μ L cell lysis buffer. The chemiluminescence detection, as described in the titration of pseudoviruses, was performed to detect the RLU values. Each group contained three replicates and these experiments were performed three times independently.

The day before neutralization assays, the BHK21-hACE2 cells were seeded into 96-well culture plates at an appropriate density. The SARS-CoV-2 pseudoviruses were incubated with serial-diluted sera at 37 for 1h in 96-well white flat-bottom culture plates and then mixed with 

The DNA sequence encoding SARS-CoV-2 S residues 1-1208 (GenBank MN908947 nucleotides

We constructed the sequences carrying 6 mutations (S 6 ) and 15 mutations (S 15 ) through rigorous bioinformatics calculation. The sequences were synthesized and constructed between Hind III and Not I site into GS-KS001 plasmid (Quacell biotechnology). Then, the CHO-K1 cells were transfected with the S wt , S 6, or S 15 plasmids by Bio-Rad Gene Pulser Xcell system, respectively.

The S wt protein was purified by Ni-NTA columns (Genscript). The S 6 or S 15 proteins were purified by anion-exchange column (Tosoh) and Hitrap Capto Core400 (Thomas Scientific). The purified S wt , S 6, or S 15 proteins were quantified by ELISA assay (Thermo Fisher Scientific) and stored at -80 .

Female K18-hACE2 transgenic mice were obtained from GemPharmatech Co., Ltd, Jiangsu

Province. For antigen formulation, 5 μ g S wt, S 6, or S 15 proteins were mixed with an equal volume of Al(OH) 3 for each mouse, respectively. The K18-hACE2 or BALB/C mice aged 6-7 weeks were immunized twice by intramuscular injection (100 μ L in each of the left and right quadriceps femoris muscles per mouse) at 2 weeks apart. Total serum anti-S IgG titer was detected by ELISA assay using custom 96-well plates coated with S protein purchased from SinoBiologic.

The SARS-CoV-2 S-trimer profile (PDB: 6XR8) was downloaded from Protein Data Bank (PDB).

The structural figures were obtained using the PyMOL Molecular Graphics System, Version 1.0.

Evolutionary dynamics of SARS-CoV-2 variants from the ongoing COVID-19 pandemic were available at https://www.gisaid.org/phylodynamics/global/nextstrain/. In brief, the visualization only contained 3815 genomes in a single view for performance and legibility reasons (49, 50). The frequencies of SARS-CoV-2 variants in the first week of each month were recorded and the analysis was performed using Graph Pad 8.0.

The peptide sequences of SARS-CoV-2 spike protein were downloaded from GISAID till

December 5 th 2021. The original data exactly matched the "FASTA header format" and was used in the further analysis. MAFFT (v7.487) was used to align each peptide sequence to the reference sequence (Wuhan-Hu-1/2019), and the mutation information was parsed using a custom python script. We analyzed 46 kinds of monomer mutations contained in 7 kinds of combined mutants and classified each sequence according to the submission date which indicated the occurrence of these monomeric mutations (ignored mutations in other locations). To improve the accuracy, a sequence was discarded if it misses sequence information in any of annotated monomer mutation sites. For the statistics of the appearance time of the wild-type sequence, we required it to be completely consistent with the reference sequence. , , , were monitored for 14 days or until body weights lost more than 25% (n=4-5 in each group). b.

The geometric mean titer (GMT) analysis of the NT 50 for S 6 vaccinated mice sera against VOC and VOI pseudoviruses (n=10). The lines indicated the NT 50 titer of the same sample. Moreover, the numbers indicated the GMTs. c. The body weighs and survival curves of mice described in a.

d. The viral genome copy numbers of SARS-CoV-2 N were quantified. Values represent means ± SD of 4-5 individual mice. The body weights are present as the mean percentage of weight change ±SEM and survival curves are shown. *P < 0.05; **P < 0.01; and ***P < 0.001. Statistical analysis, two-way ANOVA for weight curves and bar graphs, and the log-rank test for survival curves. O c t -2 0 2 0 N o v -2 0 2 0 D e c -2 0 2 0 J a n -2 0 2 1 F e b -2 0 2 1 M a r -2 0 2 1 A p r -2 0 2 1 M a y -2 0 2 1 J u n -2 0 2 1 J u l -2 0 2 1 A u g -2 0 2 1 S e p -2 0 2 1 S e p -2 0 2 0 A u g -2 0 2 0 J u l -2 0 2 0 J u n -2 0 2 0 M a y -2 0 2 0 A p r -2 0 2 0 M a r -2 0 2 0 F e b -2 0 2 0 J a n - Omicron(B.1.1.529+BA.*) R 2 4 6 I K 4 1 7 N E 4 8 4 K N 5 0 1 Y A 7 0 1 V L 1 8 F T 2 0 N P 2 6 S D 1 3 8 Y R 1 9 0 K 4 1 7 T E 4 8 4 K N 5 0 1 Y H 6 5 5 Y T 1 0 2 7 I Q 5 2 R d e l 6 9 -7 0 E 4 8 4 K Q 6 7 7 H F 8 8 8 L T 9 5 I E 1 5 4 K L 4 5 2 R E 4 8 4 Q P 6 8 1 R T 1 9 R d e l 1 5 7 d e l 1 5 8 d e l 1 5 7 -1 5 8 L 4 5 2 R T 4 7 8 K P 6 8 1 R D 9 5 0 N G 7 5 V T 7 6 I R 2 4 6 N d e l 2 4 7 -2 5 3 L 4 5 2 Q F 4 9 0 S T 8 5 9 N 

Eta (B.1.525) Kappa (B.1.617.1) Delta (B.1.617.2)

YP 009724390.1 |WT(Wuhan-Hu-1) QHR63260.2 |WT(WIV04)

UCU68808.1 |Beta(B.1.351)

QWU72474.1 |Lambda(C.37) UFJ50478.1 |Lambda(C.37)

QRF70806.1 |Eta(B.1.525) UEC87680.1 |Eta(B.1.525)

UEF62508.1 |Kappa(B.1.617.1) QQX12069.1 |Gamma(P.1)

QTS25314.1 |Kappa(B.1.617.1) UEC87919.1 |Gamma(P.1)

QQH18533.1 |Alpha(B.1.1.7)

This work was supported in part by the National Key R&D Program (2018FYA0900801 and 2018FYA0900803 to K.X.), the Innovation Team Research Program of Hubei Province (2020CFA015 to K.L. and K.X.), the National Natural Science Foundation of China (grants